Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis

被引：2

作者：

Young, Jennifer ^{[1
]}

Sawyer, Jaclyn ^{[1
]}

Jenkins, Meredith ^{[1
]}

O'Brien, Maureen ^{[2
,3
]}

Luchtman-Jones, Lori ^{[3
,4
]}

Breese, Erin H. ^{[2
,3
]}

机构：

[1] Cincinnati Childrens Hosp Med Ctr, Div Pharm, 3333 Burnet Ave,MLC 15010, Cincinnati, OH 45209 USA

[2] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, Cincinnati, OH 45209 USA

[3] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA

[4] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Hematol, Cincinnati, OH 45209 USA

来源：

PEDIATRIC BLOOD & CANCER | 2019年 / 66卷 / 06期

关键词：

antithrombin III; asparaginase-induced thrombosis; capped antithrombin III; ACUTE LYMPHOBLASTIC-LEUKEMIA; VENOUS THROMBOEMBOLISM; SUPPLEMENTATION;

D O I：

10.1002/pbc.27719

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Asparaginase therapy induces a transient antithrombin III (ATIII) deficiency, which contributes to the risk of asparaginase-induced thrombosis. At Cincinnati Children's Hospital Medical Center, management of asparaginase-induced thrombosis includes ATIII supplementation during therapeutic anticoagulation with enoxaparin. Due to the expense associated with ATIII, a capped dosing approach for ATIII was evaluated in this population. Peak ATIII levels were obtained following capped doses to evaluate response. In this pilot evaluation, 11 patients received a total of 138 capped doses for a total cost savings of $803 782. This pilot evaluation represents the first reported analysis of capped ATIII dosing in oncology patients.

引用

页数：3

共 39 条

[1] AsparaginaseHyperglycaemia, asparaginase-associated pancreatitis and cerebral thrombosis: 7 case reports
Reactions Weekly, 2022, 1905 (1) : 91 - 91
[2] Management Practices for Asparaginase-associated Coagulopathy: A Survey of Pediatric Oncologists
Greenmyer, Jacob R.
Wyatt, Kirk D.
Rodriguez, Vilmarie
Ashrani, Aneel A.
Warad, Deepti
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (08) : E1023 - E1028
[3] MANAGEMENT OF ASPARAGINASE-ASSOCIATED COAGULOPATHY AMONG PEDIATRIC ONCOLOGY PROVIDERS
Greenmyer, Jacob
Rodriguez, Vilmarie
Ashrani, Aneel
Wyatt, Kirk
Warad, Deepti
PEDIATRIC BLOOD & CANCER, 2021, 68 : S85 - S85
[4] Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia
Merryman, Reid
Stevenson, Kristen E.
Gostic, William J., II
Neuberg, Donna
O'Brien, Jane
Sallan, Stephen E.
Silverman, Lewis B.
PEDIATRIC BLOOD & CANCER, 2012, 59 (05) : 925 - 927
[5] Asparaginase-Associated Myelosuppression and Effects on Dosing of Other Chemotherapeutic Agents In Children and Adolescents with Acute Lymphoblastic Leukemia
Merryman, Reid
Gostic, William J., II
Stevenson, Kristen E.
Neuberg, Donna
O'Brien, Jane
Sallan, Stephen E.
Silverman, Lewis B.
BLOOD, 2010, 116 (21) : 1332 - 1333
[6] Coronary thrombosis associated with antithrombin-III deficiency
Loubser, PG
McCarthy, JJ
Attar, M
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1997, 11 (06) : 756 - 759
[7] Immediate Transfer for Clot Extraction in a Young Woman With Leukemia and Asparaginase-Associated Acute Cerebral Vein Thrombosis
Kasischke, Karl A.
Peguero, Edwin N.
Sriaroon, Chakrapol
Moreo, Natalie
Ren, Zeguang
Mokin, Maxim, V
Rose, David Z.
NEUROHOSPITALIST, 2020, 10 (01): : 58 - 63
[8] MESENTERIC VENOUS THROMBOSIS ASSOCIATED WITH ANTITHROMBIN-III DEFICIENCY
MATEO, O
LAGO, J
DETOMAS, J
ALONSO, A
DUQUE, C
TUREGANO, F
BRITISH JOURNAL OF SURGERY, 1995, 82 : 141 - 141
[9] CEREBRAL VENOUS THROMBOSIS ASSOCIATED WITH ANTITHROMBIN-III DEFICIENCY
LEE, MK
NG, SC
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1991, 21 (05): : 772 - 773
[10] DEFICIENCY OF ANTITHROMBIN III ACTIVITY ASSOCIATED WITH HEREDITARY THROMBOSIS TENDENCY
KAULLA, EV
KAULLA, KNV
JOURNAL OF MEDICINE, 1973, 3 (06) : 349 - 358

← 1 2 3 4 →